At a glance
- Originator Merck & Co
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy; Stroke
Most Recent Events
- 19 Nov 1997 No-Development-Reported for Epilepsy in United Kingdom (Unknown route)
- 19 Nov 1997 No-Development-Reported for Stroke in United Kingdom (Unknown route)
- 12 May 1995 Preclinical development for Epilepsy in United Kingdom (Unknown route)